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ABSTRACT 
The densities of CD3
+ 
and CD8
+ 
tumor-infiltrating lymphocytes (TILs), combined with TNM 
(tumor-node-metastasis) staging, have prognostic value for nonmetastatic colorectal cancer (CRC) 
patients. We compared the prognostic value of CD3
+
 and FoxP3
+
 TILs at the invasive front, TNM 
classifiers, and microsatellite (MS) status in a trial set of patients with stage II-III CRC (n = 413), 
by recursive partitioning with a classification and regression tree (CART). Significant prognostic 
factors and interactions were re-assessed by logistic regression and Cox proportional-hazards 
modeling in the trial and a validation set (n = 215) of patients with stage II CRC. In the trial set, 
CART
 
indicated that TIL numbers were of value only in predicting recurrence risk for stage II 
cancers, where low densities of FoxP3
+
 TILs ranked first and low densities of CD3
+
 TILs further 
stratifiying risk. Multivariate analysis showed that TILs interacted with tumor stage (FoxP3
+
, P = 
0.06; CD3
+
, P = 0.02) and MS instability (FoxP3
+
; P = 0.02). In stage II MS-stable cancers, 
concomitant low densities of both FoxP3
+
 and CD3
+
 TILs identified patients with the highest 
progression risk in the trial (HR 7.24; 95%CI, 3.41-15.4; P < 0.001) and the validation (HR 15.16; 
95% IC, 3.43-66.9; P < 0.001) sets. FoxP3
+ 
and CD3
+
 TIL load in CRC was more informative than 
other prognostic factors before the cancer progressed to lymph nodes. This prognostic information 
about TILs, including FoxP3
+
 cells, suggests that randomized controlled trials might be refined to 
include interactions between TNM status, molecular classifiers, and post-surgical treatments.   
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INTRODUCTION 
Translational studies have clarified the role of the local immune response in controlling the 
progression of colorectal cancer (CRC). High intra- and peri-tumoral densities of CD3
+
 T-cells, 
CD8
+
 cytotoxic lymphocytes and memory CD45RO
+
 cells predict a better postsurgical outcome [1, 
2]. Densities of CD3
+
 and CD8
+
 cells at these locations defined an immunoscore assessing the 
extent of the anti-tumor response in early CRC that was more informative than the analysis of a 
single T-cell population at a given location [3]. With a retrospective analysis of CRC cohorts [4], an 
international consortium presented Immunoscore as a reliable predictor of cancer recurrence in 
patients with nonmetastatic CRC and an improvement upon the prognostic power of conventional 
TNM (T, size and spread of primary cancer; N, number of metastatic lympho nodes; M, metastases 
spread to distant organs) staging [5].  
Although not included in Immunoscore, high densities of FoxP3
+
 tumor infiltrating lymphocytes 
(TILs) predict a favorable CRC outcome [6-13]. The positive prognostic value of FoxP3
+ 
TILs is 
counter-intuitive, given that the expression of the Foxp3
+
 transcription factor is typical of T-
regulatory cells (T-regs), an immunosuppressive population associated with poor prognosis in other 
cancers [14].  
Before FoxP3
+
 TILs can function as an immune biomarker predictive of CRC outcome, their 
prognostic value needed to be analyzed. First, densities of FoxP3
+
 TILs might be influenced by the 
tumor microsatellite (MS) status [6, 8, 15]. Indeed, FoxP3
+
 TILs had no prognostic value for CRC 
with MS-instability (MSI) in a study stratified by tumor mismatch-repair status [7]. Second, the 
prognostic value of FoxP3
+
 TILs is unclear in the context of nodal involvement, which may reflect 
tumor immune evasion [16]. In patients with stage II/III CRC, FoxP3
+
 TILs presented as a stage-
independent prognostic factor, although stages II and III were not separately analyzed [6]. Finally, 
the interaction of FoxP3
+
 with other T cells is unclear. Densities of FoxP3
+
 TILs predicted survival 
of patients with early CRC independently of, and more accurately than, densities of CD8
+
 and 
CD45RO
+
 TILs in one study [6], but were less informative than densities of CD45RO
+
 TILs in 
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another study [8]. FoxP3
+
 TILs were also reported to significantly interact with the prognostic value 
of CD8
+
or CD3
+ 
TILs [9, 11, 12]. The aim of this study was to see whether densities of FoxP3
+
 
cells at the invasive tumor front can add to the prognostic significance of CD3
+
 TILs in a patient 
series of pT3/pT4 CRC stratified by nodal involvement and MS status.  
PATIENTS AND METHODS 
Study population. The trial set included formalin-fixed, paraffin-embedded (FFPE) tumor 
specimens from 413 consecutive patients with stage II-III pT3-T4 CRC who had received radical 
surgery at the Humanitas Clinical and Research Center, from 1997 to 2006. 
The external validation set included tissues of stage II CRC from 215 consecutive patients who had 
undergone surgery from 2010 to 2015 at the St. Orsola-Malpighi Hospital in Bologna (n=74), or 
from 2008 to 2014 at the Grande Ospedale Metropolitano Niguarda in Milan (n=141). 
The absence of metastasis at diagnosis was assessed definitively in all patients by combining 
histopathological findings, surgical records, and perioperative imaging (abdominal CT and chest 
radiography in all patients). The observation period started immediately after surgery. To monitor 
postsurgical tumor recurrences, thoraco-abdominal CT, abdominal ultrasonography, and chest 
radiography were done according to common protocols for surveillance. Patients with rectal cancer 
treated with neo-adjuvant radiotherapy were not included in the study. Five-fluorouracil 
chemotherapy was administered on clinical grounds and not in the context of prospective trials. 
MS-status was systematically assessed by analysis of mononucleotide repeats.  
MSI assignment was based on the analysis of repeats in mononucleotides BAT26 and BAT25. 
DNA was purified from paraffin sections of formalin-fixed tissue with a neoplastic cell content 
above 50%.  After DNA extraction by proteinase-K digestion, BAT26 and BAT25 loci were 
amplified by fluoresceinated primers, and PCR products analyzed by capillary electrophoresis (ABI 
PRISM 310 DNA Sequence; PE Applied Biosystems). Finally, the MSI phenotype tumours  were 
investigated for MMR protein defects by immunohistochemistry [17, 18].  
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Ethics approval and consent to participate. The study was conducted in accordance with the 
Helsinki Declaration on ethical principles for medical research involving human subjects. Samples 
from both the internal and external set were obtained complying with protocols approved by the 
local Ethical Committee and Institutional Review Board at Humanitas Clinical and Research Center 
(approval no. 1052 and further acknowledgment of 14 May 2013). All patients provided their 
informed consent to the referring physician or to other clinicians involved in the study at each 
participating center. 
Immunohistochemistry. Formalin-fixed, paraffin-embedded, and 2-μm thin sections of tumour 
were deparaffinized and exposed to an antigen-retrieval system (1 mmol/L ethylenediamine 
tetraacetic acid, pH 8, for 30 min at 98°C). Endogenous peroxidase was blocked with 3% hydrogen 
peroxide for 10 min at room temperature; non specific staining was reduced with Background 
Sniper (Biocare Medical, The Netherlands) for 15 min at room temperature. Then, slides were 
incubated for 60 min at room temperature in moist chamber with the specific antibodies for CD3 
(1:50, clone F7238; Dako, Italy) and FoxP3 (dilution 1:100, clone 236/E7, Abcam, UK), or mouse 
IgG (Dako, Italy) for negative controls. To reveal bound antibodies the slides were exposed to 
MACH 4 Universal HRP Polymer system (Biocare Medical, the Netherlands) following 
manufacturer’s instructions, followed by incubation with DABchromogen X50 (Dako, Italy) as 
chromogen. Finally, nuclei were lightly counterstained with a freshly made hematoxylin solution 
(Harris Hematoxylin, DiaPath, Italy). 
Image analysis. From whole tissue slides, we obtained digital images of three randomly chosen, 
non-adjacent, non-overlapping areas at the tumor invasive front. The selected areas had to include 
50% of tumor gland and 50% of bordering stroma. The observer who selected the areas of interest 
was blinded to tumor microsatellite status and to any patient clinical data. The Image-Pro Premier 
9.2 (Media Cybernetics, Rockville, MD, USA) analysis software calculates on the total digital 
captured area the percentage of TIL immune-reactive area (IRA%) on the basis of red, green, and 
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blue color segmentation. For each specimen, the average IRA% from the three different areas was 
calculated and used for subsequent statistical analysis.  
Statistical analysis. We weighed the relationship between IRA% of CD3
+
 and FoxP3
+
 TILs by 
linear regression, and assessed their association with patient demographics, clinical-pathological 
features at diagnosis by Wilcoxon/Mann-Whitney test.  
For evaluating CD3
+ 
and FoxP3
+
 TIL densities as prognostic factors, we first used recursive 
partitioning analysis to identify foretelling variables. These variables included patient demographics 
and clinical-pathological tumor features, assessed by the CART (Salford Systems, San Diego, CA, 
USA) software, which also identifies cutoff values for continuous variables. CART, commonly 
used in data mining, was used to build a model predicting the likelihood of recurrence (dependent 
variable) testing several independent variables (i.e., demographics, clinical, pathological, molecular 
features, and TIL densities) [19, 20]. The algorithm weights each independent variable in predicting 
the dependent one, moving along a tree-like decision structure. In the decision tree, each node 
hierarchically identifies the independent variable with the best predictive value. From each node, 
branches emerge, as long as predictive variables can be identified. Afterward, the prognostic values 
of CD3
+
 and FoxP3
+
 TILs densities were re-tested by logistic regression, and the variables 
significantly associated with disease relapse at univariate analysis were entered in a multivariate 
model including possible interactions. Independent predictors of disease-free survival (DFS) were 
tested in a Cox proportional-hazards  [21] model to evaluate progression. DFS was calculated from 
diagnosis until March 1
st
, 2013, which was the date of data censoring for the trial set, and December 
31
st
 2017 for the validation set. To analyze the survival of CRC patients grouped according to TIL 
density, we plotted Kaplan-Meier curves and obtained the relative Log-rank tests. All statistical 
analyses except for recursive partitioning were managed by STATA (version 13.1). Two-sided P 
values of < 0.05 were considered statistically significant. 
RESULTS 
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Densities of FoxP3
+
 and CD3
+
 TILs by patient demographics and tumor features. 
Variable densities of CD3
+
 TILs were detectable at the invasive front of 97.3% of tissues from the 
trial set (402 of 413), and FoxP3
+ 
TILs were detected in 82.3% (340 out of 413) of tissues. Linear 
regression analysis showed no significant correlation (p=0.26) between the density of FoxP3
+ 
TILs 
(median, 0.37%; 2
nd
-3
rd
 quartile, 0.13-0.68) and the density of CD3
+
 TILs (median, 2.42%; 2
nd
-3
rd
 
quartile, 0.92-5.78). 
Densities of FoxP3
+
and CD3
+
 TILs by patient demographics and tumor molecular/pathological 
features are detailed in Supplementary Table S1. MSI correlated with a higher density of CD3
+
 
TILs (P < 0.001) and with lower densities of FoxP3
+
 cells (P < 0.001). No FoxP3
+ 
immuno-
reactivity was detectable in 21 of 66 (31.8%) of these tumors. 
Data mining for the prognostic impact of TILs in stage II/III CRC. 
CART
 
analysis (Fig. 1) identified TNM staging as the highest hierarchical node (odds ratio (OR), 
2.97; 95%CI, 1.85-4.77; p<0.001) in the prognostic tree, stage III accounting for 70 of 102 (68.6%) 
postoperative recurrences. Densities of FoxP3
+
 TILs or CD3
+
 TILs had no predictive value in stage 
III CRC, in which only nodal status had further predictive value (N2 vs. N1; OR, 3.56; 95%CI, 
1.93-6.58; P < 0.001). In contrast, both FoxP3
+
 and CD3
+
 TILs had a place in the prognostic tree of 
stage II CRC. Low densities of FoxP3
+
 cells ranked first in this decisional branching (OR 5.20; 
95%CI, 2.26-11.9; P < 0.001), identifying 23 of 32 (71.9%) recurrences. Secondary branching of 
low-FoxP3
+
 tumors by CD3
+
 TILs further improved the identification of recurrences (OR, 4.46; 
95%CI, 1.58-12.6; P < 0.001). The combination of low densities for both Foxp3
+
 and CD3
+
 TILs 
predicted 16 of 32 (50.0%) recurrences with 20 of 179 (11.2%) false positives, and thus 83% 
accuracy.  
Analytical assessment of prognostic variables and of their interactions.  
At logistic regression analysis (Supplementary Table S2), postoperative recurrences were 
significantly associated with lower (below median) densities of FoxP3
+
 (OR, 2.24; 95%CI, 1.41-
3.56; P < 0.001) and CD3
+ 
TILs (OR, 1.59; 95%CI, 1.01-2.50; P = 0.04). Other variables 
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significantly associated with recurrences included stage III (P < 0.001), pT4 local invasion (0.03), 
and angio-invasion (p=0.002). A protective effect was observed for MSI (P = 0.05). At multivariate 
analysis, densities of both FoxP3
+
 and CD3
+ 
TILs interacted with tumor stage (P = 0.06 and P = 
0.02, respectively), densities of FoxP3
+
 cells significantly interacting also with the MS-status of 
stage II CRC (0.03). A stratified analysis showed that below-median densities of FoxP3
+
 and CD3
+ 
TILs were associated with disease progression in patients with stage II MS-stable (MSS) CRC, but 
not in patients with MSI or stage III cancer (Table 1).  
ROC curve analysis confirmed that densities of TILs can predict postsurgical progression in 
patients with stage II MSS CRC (Fig. 2), the area under the curve (AUC) being 0.77 for FoxP3
+
 
cells and 0.71 for CD3
+ 
cells. The estimation of the cutoffs returned values of IRA% matching those 
adopted by the CART. ROC analysis also confirmed the absence of any predictive value of TILs in 
stage II MSI cancers (AUC: 0.45 for FoxP3
+
; 0.53 for CD3
+
 TILs), and in stage III tumors (AUC: 
0.55 and 0.53, respectively).  
At Cox proportional-hazards model [21] (Table 2), low densities of FoxP3
+
 and CD3
+
 TILs, as 
defined by ROC cutoffs, were both independent predictors of poor disease-free survival (DFS) in 
stage II MSS CRC (FoxP3
+
: hazard ratio (HR), 5.61; 95%CI, 2.38-13.2; P < 0.001- CD3
+
: HR, 
5.76; 95%CI, 2.16-15.35; P < 0.001). Deep local invasion (pT4) was the only additional predictor 
of recurrence (HR, 3.88; 95%CI, 1.29-11.7; P = 0.02). Tumors with high densities of both FoxP3
+
 
and CD3
+
 TILs had no recurrence. The outcome of cancers with a discordant pattern of TILs 
(high/low or low/high densities) was better than that of tumors with low densities for both FoxP3
+
 
and CD3
+
 TILs. As a result, coexisting low densities of both TIL markers provided the strongest 
predictor of poor outcome (HR, 7.24; 95%CI, 3.41-15.4; P < 0.001, vs. all other combinations). The 
recurrence rate of cancers with low densities for both FoxP3
+
 and CD3
+
 TILs (50%) exceeded the 
sum of the recurrence rate of tumors with discordant densities (15%), as observed in additive 
models of biological interaction.  
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Kaplan-Meier curves (Fig. 3) recapitulated statistical analysis by showing that stage II and MSS 
CRC (Fig. 3A) harboring both low-density FoxP3
+
 and low-density CD3
+
 TILs, had a 5-year DFS 
lower than 60%, which was worse than that of tumors with high densities for both cell types (100% 
5-year DFS; P < 0.001) or discordant densities (85% 5-year DFS, P < 0.001). Conversely, TILs 
densities did not predict DFS of patients with stage III MSS CRC (Fig. 3B), nor that of subjects 
with MSI cancer (Fig. 3C). 
Data validation in the external set of stage II MSS CRC. 
In the external validation set of stage II MSS CRC, demographics and tumor pathological features 
showed no significant association with densities of FoxP3
+
 and CD3
+
 cells (Supplementary Table 
S3). ROC curve analysis showed that AUC of FoxP3
+
 and CD3
+
 TILs (0.78 and 0.71, respectively) 
were superimposable to those computed from corresponding tumors of the trial set (Supplementary 
Fig. S1). Cox multivariate analysis employing trial set cutoffs confirmed that both FoxP3
+
 (HR 
5.15; 95%CI, 1.94-13.7; P = 0.001) and CD3
+ 
(HR 2.78; 95%CI, 1.23-6.28; P = 0.001) TILs are 
independent predictors of recurrence (Supplementary Table S4). Again, the combination of low-
density FoxP3
+ 
and low-density CD3
+
 TILs predicted the worst outcome (HR 5.31; 95%CI, 2.45-
11.5; P < 0.001), as confirmed by Kaplan-Meier curves (Fig. 3D). 
The prognostic value of TILs was independent of adjuvant therapy. Kaplan-Meier curves of 327 
patients with stage II MSS CRC (a cohort arrived at by merging the trial and validation sets) 
showed that combined information about density of FoxP3
+ 
and CD3
+
 TILs predicted DFS in 
treated (n = 119, 36.4%) and untreated patients (Supplementary Fig. S2).  
DISCUSSION 
Studies have shown that the extent of the local immune response to CRC is a determinant of the 
patient outcome [1-3, 5, 16, 22]. The present study demonstrates that postoperative recurrences are 
better predicted by densities of FoxP3
+
 TILs at the invasive front of stage II MSS CRC than by 
CD3
+
 TILs. By introducing the concept of a synergistic interaction of FoxP3
+
 and CD3
+
 TILs in 
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determining the protective effect of the local immune response, this work supports the inclusion of 
the density of FoxP3
+
 cells as a prognostic variable.  
Following a meta-analysis supporting the prognostic value of FoxP3
+
 TILs [23], our study 
demonstrates the prognostic value of FoxP3
+
 TILs at the tumor front of stage II CRC through the 
analysis of whole-tissue sections and by statistical analysis. The statistical analysis included 
recursive partitioning, which weighs the impact of a candidate marker by allowing for interactions 
with other prognostic variables [24]. The results were confirmed by conventional multivariate and 
interaction models. The lack of correlation between the densities of FoxP3
+
 and CD3
+
 TILs along 
with their different association with MSI do not suggest that infiltration by FoxP3
+
 cells is a simple 
homeostatic response to an effective T-cell recognition. Rather, our data suggest individual 
recruitment of FoxP3
+
 and CD3
+
 TILs, which then synergistically interact in protecting against 
cancer progression [25].  
Even though high density of FoxP3
+
 TILs correlates with improved outcomes in patients with stage 
II CRC, FoxP3
+
 TILs are also associated with immunosuppressive functions. Indeed, FoxP3 is 
expressed by activated effector T cells [26] and by T cells that, once sorted from CRC, inhibit IFN 
production and T-cell proliferation [27]. The latter are bona fide immunosuppressive Tregs. Colonic 
microflora can also divert T-cell killing activity away from cancer cells [28]. Therefore, it has been 
proposed that FoxP3
+
 Tregs trimmed by the colonic milieu may attenuate the Th17-mediated pro-
inflammatory and tumor-enhancing response induced by bacterial exposure [10, 15], thus freeing 
other TILs to target antigens expressed by cancer cells. Consistent with this view, T-regs induced 
tumor regression in a mouse model of intestinal polyposis [29]. In addition to their regulatory 
functions modulating the immune response to the colonic commensal microflora, FoxP3
+
 cells 
could activate effector and memory TIL abilities rather than suppressor functions [30]. Effector and 
memory TILs are otherwise associated with Treg cells shaped by microenvironmental stimuli, and 
require a complex mix of phenotypic features for their proper identification [31]. 
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Various factors slow the introduction of immune-based prognostic markers into the clinical routine. 
Consensus on which T-cell subsets and locations best serve for prognosis in CRC is lacking. 
Indeed, a meta-analysis confirmed the prognostic value of the immune infiltrate but did not validate 
the individual impact of T-cell subtypes and sites [32].  
Densities of CD3
+
 and CD8
+
 cells within the tumor and at the invasive margin were proposed as 
informative for CRC prognostication [3] and adopted by the Immunoscore consortium [4, 5]. Our 
results endorse the inclusion of FoxP3
+
 cell into the panel of markers aimed at predicting 
recurrences of stage II CRC.  
The most controversial issue is the prognostic value of TILs densities across TNM stages. In the 
present study, TILs stratified patient survival across stage II and III, but neither CD3
+
 nor FoxP3
+
 
TILs had prognostic value in stage III CRC. This stands in conflict with studies reporting that CD3
+
 
and FoxP3
+
 TILs have prognostic value independent of CRC stage [2, 7, 8, 33] and to some extent 
in conflict with the Immunoscore results [5], in which stage III CRCs were under-represented, and 
increasing nodal involvement modified patient outcome independently of the Immunoscore with 
multivariate analysis. In a scenario in which the interaction between nodal invasion and prognostic 
value of TILs is overlooked, it would be assumed that the magnitude of the local immune reaction 
controls tumor progression across stages with unmodified efficiency. Our results contradict this 
notion and support the integration of immunometric data with the TNM system. Furthermore, other 
immune cells, such as tumor-associated macrophages, tertiary lymphoid tissue [34], and 
neutrophils, modify cancer cell behavior [35] and may predict the outcome for patients with stage 
III CRC [36].  
At present, neither discordant biological theories nor the lack of clarity on the hierarchical 
positioning of the immune markers vs. the TNM system should delay the implementation of studies 
needed to complete the validation of the best immunoscore for stage II CRC. Neither FoxP3
+
 nor 
CD3
+ 
cells have a prognostic impact in MSI CRC, so that the exclusion of these cancers strengthens 
the predictive power of TILs. TIL analysis in stage II CRC would be prognostically efficient even 
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in the absence of MSI screening, due to the low recurrence rate of mismatch-repair deficient 
cancers, explained by persistent renewal of neo-antigens to improve immune surveillance [37]. At 
any event, universal screening for MSI is currently an advocated standard [38, 39], so that TNM 
classification would be best empowered by the parallel inclusion of TILs and MS-status assessment.  
Features that pose the greatest risk of excluding patients with stage II CRC from such assessment 
include inadequate sampling of lymph nodes, poorly differentiated histology, pT4 invasion, and 
perforation [40]. None of these confers a risk of recurrence superior to that reported for immune 
markers by large reference studies. Accordingly, we found that the prognostic impact of low-
FoxP3
+
-CD3
+
 TILs in stage II MSS CRC exceeded the weight of pT4. This reinforces the concept 
that only the introduction of a prognostic immunoscore can optimize the benefits of adjuvant 
therapy in stage II CRC. Although the limited number of patients with stage II cancers treated with 
adjuvant therapy does not allow for conclusive answers, our results suggest that the immune 
response is more relevant than chemotherapy in determining the outcome of stage II CRC. Thus 
therapeutic efforts and innovative approaches should focus on patients with low TIL loads. Such 
approaches might include the use of interleukins (IFN-γ) and/or antibodies (anti-CTL4 or anti-PD-
1) to boost the immune response of patients with MSS CRC. Patients with MSI CRC might benefit 
not only from anti-PD1 therapies but also from vaccination strategies based on frameshifted 
peptides. 
Our results from implementation of Immunoscore and including information about FoxP3
+
 TILs 
suggest the value of further testing within randomized controlled trials, such as those of the TOSCA 
trial [41] and of the IDEA collaboration [42].  
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Table 1. Tumor densities of FoxP3
+
 and CD3
+
 TILs as predictors of CRC post-surgical recurrence, stratified by tumor stage and MS-status 
a
. 
 
Stage II 
 
Stage III (n=202) 
MSS (n=170) 
 
MSI (n=41) 
 
Rate of 
recurrence (%) 
OR (95%CI) p  
Rate of 
recurrence (%) 
OR (95%CI) p  
Rate of 
recurrence (%) 
OR (95%CI) p 
                
FoxP3
+ 
TILs above median 4/86 (4.7) 1.00 ref.   2/21 (9.5) 1.00 ref.   29/101 (27.7) 1.00 ref.  
 below median 24/84 (28.6) 8.75 (2.74-28.0) <.001  2/20 (10.0) 1.36 (0.15-12.4) .79  41/101 (40.6) 1.60 (0.86-2.96) .14 
                
CD3
+ 
TILs above median 5/85 (5.9) 1.00 ref.   2/21 (9.5) 1.00 ref.   35/101 (34.7) 1.00 ref.  
 below median 23/85 (27.1) 6.78 (2.26-20.4) .001  2/20 (10.0) 0.78 (0.08-7.25) .83  35/101 (34.7) 0.88 (0.47-1.63) .68 
                
Local Invasion pT3 24/160 (15.0) 1.00 ref.   2/33 (6.1) 1.00 ref.   
NS 
 pT4 4/10 (40.0) 4.89 (0.94-24.4) .05  2/8 (25.0) 5.71 (0.59-55.2) .13  
                
Nodal status N1 
NA 
 32/131 (24.4) 1.00 ref  
 N2  38/71 (53.5) 3.48 (1.87-6.46) <.001 
        
a logistic regression, multivariate analysis 
NA, not applicable 
NS, variable not qualified (p>.10) for being entered into multivariate analysis of stage III CRC 
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Table 2. Low densities
a
 of FoxP3
+
 and CD3
+ 
TILs, and their combination, to predict disease-
free survival (DFS) in stage II MSS CRC. 
 
Rate of 
recurrence (%) 
 HR (95%CI) b p 
     
FoxP3
+
 TILs high 7/109 (6.4)  1.00, ref.  
 low 21/61 (34.4)  5.61 (2.38-13.2) <.001 
       
CD3
+
 TILs high 5/87 (5.8)  1.00, ref.  
 low 23/83 (27.7)  5.76 (2.16-15.3) <.001 
       
       
FoxP3
+
/CD3
+
 TILs high/high 0/58 (0.0)  
1.00, ref. 
 
 high/low 7/51 (13.7)   
 low/high 5/29 (17.2)   
 low/low 16/32 (50.0)  7.24 (3.41-15.4) <.001 
       
a defined by optimal cutoffs at ROC curves (Fig. 2): 0.23% IRA for Fox P3+ cells, 1.86% IRA for 
CD3+ cells 
b multivariate Cox regression analysis, adjusted by tumor local invasion (pT). HR values are for 
recurrence risk 
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Figure Captions 
Figure 1. Hierarchical recursive analysis of factors predicting postsurgical recurrences in 413 
patients with stage II-III CRC. Classification and regression tree (CART) modeled (Salford 
Systems, San Diego, CA, USA) by entering patient demographics, tumor pathological features 
(including MS status), as well as densities of FoxP3
+
 and CD3
+
 TILs. TNM staging (stage III vs. 
stage II) ranked as the hierarchically highest prognostic node (P < 0.001, Chi-square test). Within 
stage III, only nodal status (N2 vs. N1) was a further discriminating factor (P < 0.001). In contrast, 
the software identified cutoff values of TIL densities efficiently predicting recurrences in stage II 
CRC. In this subset, low densities of FoxP3
+ 
TILs ranked first in the decisional branching (P < 
0.001), whereas low densities of CD3
+
 TILs further discriminated the outcome of CRC with low 
density of FoxP3
+
 TILs (P < 0.001). MS status was not recognized as a discriminating predictor. 
Figure 2. ROC curves for densities of FoxP3
+
 and CD3
+
 TILs as predictors of postsurgical 
cancer recurrence in patients with stage II MSS CRC. FoxP3
+
 TILs: AUC, 0.77 (bootstrap 
standard error, 0.05; 95%CI, 0.67-0.86); at cutoff 0.23 IRA%, sensitivity, 0.79; specificity, 0.71. 
CD3
+
 TILs: AUC, 0.71 (bootstrap standard error, 0.05; 95%CI, 0.61-0.81); at cutoff 1.86 IRA%, 
sensitivity, 0.82; specificity, 0.58. 
Figure 3. Kaplan-Meier curves for the duration of disease-free survival in patients with stage 
II-III CRC. A. MSS stage II trial set cancers stratified by combined analysis of FoxP3
+
 and CD3
+
 
TIL densities (low vs. high, by cutoff at ROC curves). The outcome for patients with MSS CRCs 
harboring low densities of FoxP3
+
 cells and low densities of CD3
+
 cells was significantly worse 
than that of patients with cancers with high densities of both cell types (P < 0.001) or discordant 
TIL densities (low-high or high-low; P = 0.001). B. MSS stage III cancers stratified by combined 
analysis of FoxP3
+
 and CD3
+
 TIL densities. The outcome for patients with MSS CRCs harboring 
low densities of both FoxP3
+ 
and CD3
+
 TILs was similar to that of patients with high densities of 
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both cell types (p=0.26) or discordant TIL densities (p=0.42). C. MSI stage II/III trial set cancers, 
stratified by combined analysis of FoxP3
+
 and CD3
+
 TIL densities. The outcome for patients with 
MSI CRCs harboring low densities of both FoxP3
+ 
and CD3
+
 TILs was like that of patients with 
high densities of both cells types (p=0.26) or discordant TIL densities (P = 0.22). D. MSS stage II 
validation set cancers stratified by combined analysis of FoxP3
+
 and CD3
+
 TIL densities. The 
outcome for patients with MSS CRCs harboring low densities of both FoxP3
+
 and CD3
+
 TILs was 
significantly worse than that of cancers with high densities of both cell types (P < 0.001) or 
discordant TIL densities (P = 0.002). 
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